Introduction
Methods
Study patients
Collection of baseline information and sample
Health related Quality of life assessments
Follow‑up
Time to deterioration model
Statistical analysis
Results
Sociodemographic, clinical characteristics, and HRQoL scores at baseline
Characteristic | n (%) | Groups of Cpn IgA (n = 82) | χ2 | P | Groups of Cpn IgG (n = 82) | χ2 | P | Groups of Cpn IgAIgG (n = 82) | χ2 | P | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cpn IgA − n (%) | Cpn IgA + n (%) | Cpn IgG − n (%) | Cpn IgG + n (%) | Cpn IgA − IgG − n (%) | Cpn IgA + IgG − /IgA − IgG + n (%) | Cpn IgA + IgG + n (%) | ||||||||
Gender | 4.523 | 0.033 | 0.164 | 0.686 | 5.908 | 0.052 | ||||||||
Male | 46(56.1) | 30 (66.7) | 16 (43.2) | 12 (60.0) | 34 (54.8) | 10 (58.8) | 22 (71.0) | 14 (41.2) | ||||||
Female | 36(43.9) | 15 (33.3) | 21 (56.8) | 8 (40.0) | 28 (45.2) | 7 (41.2) | 9 (29.0) | 20 (58.8) | ||||||
Age | 1.057 | 0.304 | 1.042 | 0.307 | 0.204 | 0.903 | ||||||||
< = 60 | 45(54.9) | 27 (60.0) | 18 (48.6) | 9 (45.0) | 36 (58.1) | 9 (52.9) | 18 (58.1) | 18 (52.9) | ||||||
> 60 | 37(45.1) | 18 (40.0) | 19 (51.4) | 11 (55.0) | 26 (41.9) | 8 (47.1) | 13 (41.9) | 16 (47.1) | ||||||
BMI | 0.925 | 0.823 | 0.861 | |||||||||||
< 18.5 | 3 (3.7) | 2 (4.4) | 1 (2.7) | 1 (5.0) | 2 (3.2) | 1 (5.9) | 1 (3.2) | 1 (2.9) | ||||||
[18.5, 24) | 48(58.5) | 27 (60.0) | 21 (56.8) | 11 (55.0) | 37 (59.7) | 9 (52.9) | 20 (64.5) | 19 (55.9) | ||||||
> = 24 | 31(37.8) | 16 (35.6) | 15 (40.5) | 8 (40.0) | 23 (37.1) | 7 (41.2) | 10 (32.3) | 14 (41.2) | ||||||
Educational level | 0.023 | 0.879 | 2.726 | 0.099 | 2.875 | 0.238 | ||||||||
Primary and below | 48(59.3) | 27 (60.0) | 21 (58.3) | 15 (75.0) | 33 (54.1) | 13 (76.5) | 16 (51.6) | 19 (57.6) | ||||||
Junior high school and above | 33(40.7) | 18 (40.0) | 15 (41.7) | 5 (25.0) | 28 (45.9) | 4 (23.5) | 15 (48.4) | 14 (42.4) | ||||||
Smoker | 0.912 | 0.340 | 0.142 | 0.706 | 1.802 | 0.406 | ||||||||
No | 44(53.7) | 22 (48.9) | 22 (59.5) | 10 (50.0) | 34 (54.8) | 9 (52.9) | 14 (45.2) | 21 (61.8) | ||||||
Yes | 38(46.3) | 23 (51.1) | 15 (40.5) | 10 (50.0) | 28 (45.2) | 8 (47.1) | 17 (54.8) | 13 (38.2) | ||||||
Drinker | 0.931 | 0.335 | 2.337 | 0.126 | 0.262 | |||||||||
No | 60(73.2) | 31 (68.9) | 29 (78.4) | 12 (60.0) | 48 (77.4) | 11 (64.7) | 21 (67.7) | 28 (82.4) | ||||||
Yes | 22(26.8) | 14 (31.1) | 8 (21.6) | 8 (40.0) | 14 (22.6) | 6 (35.3) | 10 (32.3) | 6 (17.6) | ||||||
Histological type | 0.277 | 0.599 | 0.063 | 0.802 | 0.656 | |||||||||
Non-adenocarcinoma | 22(27.2) | 13 (29.5) | 9 (24.3) | 5 (25.0) | 17 (27.9) | 4 (23.5) | 10 (33.3) | 8 (23.5) | ||||||
Adenocarcinoma | 59(72.8) | 31 (70.5) | 28 (75.7) | 15 (75.0) | 44 (72.1) | 13 (76.5) | 20 (66.7) | 26 (76.5) | ||||||
TNM stage | 0.647 | 0.421 | 1.739 | 0.187 | 0.823 | 0.663 | ||||||||
0 and I | 47(57.3) | 24 (53.3) | 23 (62.2) | 14 (70.0) | 33 (53.2) | 11 (64.7) | 16 (51.6) | 20 (58.8) | ||||||
II and above | 35(42.7) | 21 (46.7) | 14 (37.8) | 6 (30.0) | 29 (46.8) | 6 (35.3) | 15 (48.4) | 14 (41.2) | ||||||
Maximum diameter of tumor | 0.115 | 0.735 | 0.163 | 0.686 | 0.972 | 0.615 | ||||||||
≤ 2.0 | 31(40.8) | 16 (39.0) | 15 (42.9) | 7 (36.8) | 24 (42.1) | 5 (31.2) | 13 (46.4) | 13 (40.6) | ||||||
> 2.0 | 45(59.2) | 25 (61.0) | 20 (57.1) | 12 (63.2) | 33 (57.9) | 11 (68.8) | 15 (53.6) | 19 (59.4) | ||||||
Therapeutic Method | 0.003 | 0.348 | 0.009 | |||||||||||
Untreated | 2 (2.4) | 1 (2.2) | 1 (2.7) | 0 (0.0) | 2 (3.2) | 0 (0.0) | 1 (3.2) | 1 (2.9) | ||||||
Surgery alone | 54(65.9) | 23 (51.1) | 31 (83.8) | 13 (65.0) | 41 (66.1) | 10 (58.8) | 16 (51.6) | 28 (82.4) | ||||||
Chemotherapy/radiation alone | 6 (7.3) | 6 (13.3) | 0 (0.0) | 0 (0.0) | 6 (9.7) | 0 (0.0) | 6 (19.4) | 0 (0.0) | ||||||
Treated with both chemotherapy/radiation and surgery | 20(24.4) | 15 (33.3) | 5 (13.5) | 7 (35.0) | 13 (21.0) | 7 (41.2) | 8 (25.8) | 5 (14.7) |
Groups of Cpn IgA (n = 82) | W | P | Groups of Cpn IgG (n = 82) | W | P | |||
---|---|---|---|---|---|---|---|---|
Cpn IgA − (M(P25,P75)) | Cpn IgA + (M(P25,P75)) | Cpn IgG − (M(P25,P75)) | Cpn IgG + (M(P25,P75)) | |||||
QLQ-C30 | ||||||||
Global health status (QL) | 83.33 (66.67, 83.33) | 83.33 (66.67, 83.33) | 910.5 | 0.325 | 66.67 (66.67, 83.33) | 83.33 (66.67, 83.33) | 386.5 | 0.008 |
Functional scales | ||||||||
Physical functioning (PF) | 93.33 (93.33, 100.00) | 93.33 (86.67, 93.33) | 1134.0 | 0.004 | 93.33 (86.67, 100.00) | 93.33 (86.67, 100.00) | 737.5 | 0.189 |
Role functioning (RF) | 100.00 (100.00, 100.00) | 100.00 (100.00, 100.00) | 815.5 | 0.814 | 100.00 (100.00, 100.00) | 100.00 (100.00, 100.00) | 590.0 | 0.627 |
Emotional functioning (EF) | 91.67 (75.00, 100.00) | 83.33 (75.00, 83.33) | 1009.5 | 0.092 | 87.50 (81.25, 93.75) | 83.33 (75.00, 97.92) | 703.5 | 0.359 |
Cognitive functioning (CF) | 100.00 (100.00, 100.00) | 100.00 (83.33, 100.00) | 887.5 | 0.482 | 100.00 (100.00, 100.00) | 100.00 (100.00, 100.00) | 678.0 | 0.390 |
Social functioning (SF) | 100.00 (66.67, 100.00) | 66.67 (66.67, 100.00) | 1082.0 | 0.010 | 83.33 (66.67, 100.00) | 66.67 (66.67, 100.00) | 698.0 | 0.354 |
Symptom scales/items | ||||||||
Fatigue (FA) | 11.11 (0.00, 22.22) | 11.11 (0.00, 33.33) | 803.5 | 0.781 | 22.22 (11.11, 33.33) | 5.56 (0.00, 22.22) | 781.5 | 0.068 |
Nausea and vomiting (NV) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 760.0 | 0.106 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 610.0 | 0.805 |
Pain (PA) | 0.00 (0.00, 16.67) | 0.00 (0.00, 16.67) | 783.5 | 0.590 | 8.34 (0.00, 16.67) | 0.00 (0.00, 16.67) | 750.0 | 0.095 |
Dyspnoea (DY) | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 755.5 | 0.409 | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 653.0 | 0.685 |
Insomnia (SL) | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 902.0 | 0.439 | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 732.0 | 0.147 |
Appetite loss (AP) | 0.00 (0.00, 0.00) | 0.00 (0.00, 33.33) | 687.0 | 0.055 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 608.0 | 0.860 |
Constipation (CO) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 901.0 | 0.160 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 640.0 | 0.641 |
Diarrhoea (DI) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 810.0 | 0.281 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 610.0 | 0.590 |
Financial difficulties (FI) | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 727.5 | 0.249 | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 587.0 | 0.678 |
QLQ-LC13 | ||||||||
Dyspnoea (LC-DY) | 0.00 (0.00, 11.11) | 11.11 (0.00, 22.22) | 649.5 | 0.066 | 0.00 (0.00, 11.11) | 11.11 (0.00, 22.22) | 528.0 | 0.286 |
Coughing (LC-CO) | 33.33 (0.00, 33.33) | 33.33 (0.00, 33.33) | 829.5 | 0.980 | 0.00 (0.00, 33.33) | 33.33 (0.00, 66.67) | 448.0 | 0.047 |
Haemoptysis (LC-HA) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 938.0 | 0.057 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 540.0 | 0.095 |
Sore mouth (LC-SM) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 869.5 | 0.203 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 641.0 | 0.407 |
Dysphagia (LC-DS) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 851.0 | 0.378 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 610.0 | 0.590 |
Peripheral neuropathy (LC-PN) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 895.5 | 0.305 | 0.00 (0.00, 33.33) | 0.00 (0.00, 0.00) | 764.0 | 0.006 |
Alopecia (LC-HR) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 828.5 | 0.903 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 600.0 | 0.431 |
Pain in chest (LC-PC) | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 778.5 | 0.554 | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 620.5 | 1.000 |
Pain in aim or should (LC-PA) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 861.5 | 0.640 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 564.0 | 0.291 |
Pain in other parts (LC-PO) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 895.5 | 0.258 | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 659.5 | 0.413 |
Groups of Cpn IgAIgG (n = 82) | H | P | |||
---|---|---|---|---|---|
Cpn IgA − IgG − (M(P25,P75)) | Cpn IgA + IgG − /IgA − IgG + (M(P25,P75)) | Cpn IgA + IgG + (M(P25,P75)) | |||
QLQ-C30 | |||||
Global health status (QL) | 66.67 (66.67, 83.33) | 83.33 (66.67, 83.33) | 83.33 (66.67, 83.33) | 3.040 | 0.219 |
Functional scales | |||||
Physical functioning (PF) | 93.33 (93.33, 100.00) | 93.33 (86.67, 100.00) | 93.33 (86.67, 93.33) | 7.531 | 0.023 |
Role functioning (RF) | 100.00 (100.00, 100.00) | 100.00 (91.67, 100.00) | 100.00 (100.00, 100.00) | 2.830 | 0.243 |
Emotional functioning (EF) | 91.67 (83.33, 100.00) | 83.33 (70.84, 100.00) | 83.33 (75.00, 83.33) | 3.247 | 0.197 |
Cognitive functioning (CF) | 100.00 (100.00, 100.00) | 100.00 (100.00, 100.00) | 100.00 (87.50, 100.00) | 1.208 | 0.547 |
Social functioning (SF) | 100.00 (66.67, 100.00) | 100.00 (66.67, 100.00) | 66.67 (66.67, 100.00) | 5.189 | 0.075 |
Symptom scales/items | |||||
Fatigue (FA) | 11.11 (11.11, 33.33) | 11.11 (0.00, 33.33) | 11.11 (0.00, 30.55) | 0.827 | 0.661 |
Nausea and vomiting (NV) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 3.920 | 0.141 |
Pain (PA) | 0.00 (0.00, 16.67) | 0.00 (0.00, 16.67) | 0.00 (0.00, 16.67) | 0.407 | 0.816 |
Dyspnoea (DY) | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 0.129 | 0.937 |
Insomnia (SL) | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 0.00 (0.00, 0.00) | 3.981 | 0.137 |
Appetite loss (AP) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 33.33) | 3.219 | 0.200 |
Constipation (CO) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 1.589 | 0.452 |
Diarrhoea (DI) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 1.412 | 0.494 |
Financial difficulties (FI) | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 1.020 | 0.601 |
QLQ-LC13 | |||||
Dyspnoea (LC-DY) | 0.00 (0.00, 11.11) | 0.00 (0.00, 11.11) | 11.11 (0.00, 22.22) | 4.002 | 0.135 |
Coughing (LC-CO) | 0.00 (0.00, 33.33) | 33.33 (0.00, 66.67) | 33.33 (0.00, 33.33) | 4.973 | 0.083 |
Haemoptysis (LC-HA) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 9.125 | 0.010 |
Sore mouth (LC-SM) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 1.756 | 0.416 |
Dysphagia (LC-DS) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 1.645 | 0.439 |
Peripheral neuropathy (LC-PN) | 0.00 (0.00, 33.33) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 5.706 | 0.058 |
Alopecia (LC-HR) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.535 | 0.765 |
Pain in chest (LC-PC) | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 0.00 (0.00, 33.33) | 0.408 | 0.816 |
Pain in aim or should (LC-PA) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 1.105 | 0.575 |
Pain in other parts (LC-PO) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 0.00 (0.00, 0.00) | 3.277 | 0.194 |
Time to deterioration and HRQoL events
The relationship between TTD and Cpn antibody
Time to deterioration event of Cpn IgAn(%) | χ2 | P | Time to deterioration of Cpn IgAM (P25, P75) | HR (95% CI) | P | |||
---|---|---|---|---|---|---|---|---|
Cpn IgA − | Cpn IgA + | Cpn IgA − | Cpn IgA + | |||||
QLQ-C30 | ||||||||
Global health status (QL) | 30 (66.7) | 22 (59.5) | 0.455 | 0.500 | 14.59 (6.11, 27.14) | 26.87 (13.37, 30.06) | 0.678 (0.385–1.192) | 0.177 |
Functional scales | ||||||||
Physical functioning (PF) | 31 (68.9) | 18 (48.6) | 3.459 | 0.063 | 9.99 (4.57, 23.95) | 24.38 (14.55, 29.40) | 0.491 (0.270–0.894) | 0.020 |
Role functioning (RF) | 21 (46.7) | 12 (32.4) | 1.711 | 0.191 | 15.74 (4.67, 29.01) | 26.87 (14.78, 30.06) | 0.575 (0.275–1.201) | 0.141 |
Emotional functioning (EF) | 16 (35.6) | 10 (27.0) | 0.682 | 0.409 | 23.03 (9.99, 30.29) | 26.87 (14.78, 30.49) | 0.604 (0.267–1.370) | 0.228 |
Cognitive functioning (CF) | 17 (37.8) | 13 (35.1) | 0.061 | 0.805 | 23.95 (11.96, 30.29) | 26.25 (14.78, 29.73) | 0.779 (0.371–1.637) | 0.510 |
Social functioning (SF) | 11 (24.4) | 7 (18.9) | 0.111 | 0.739 | 24.05 (11.96, 31.11) | 28.02 (16.36, 30.49) | 0.658 (0.241–1.798) | 0.415 |
Symptom scales/items | ||||||||
Fatigue (FA) | 17 (37.8) | 10 (27.0) | 1.063 | 0.303 | 23.03 (6.60, 29.01) | 26.87 (14.55, 30.06) | 0.573 (0.254–1.292) | 0.179 |
Nausea and vomiting (NV) | 12 (26.7) | 9 (24.3) | 0.058 | 0.809 | 23.95 (12.94, 31.08) | 28.85 (16.36, 30.49) | 0.725 (0.296–1.778) | 0.482 |
Pain (PA) | 24 (53.3) | 15 (40.5) | 1.332 | 0.248 | 12.94 (5.19, 25.95) | 24.38 (13.31, 29.70) | 0.607 (0.313–1.178) | 0.140 |
Dyspnoea (DY) | 19 (42.2) | 10 (27.0) | 2.051 | 0.152 | 23.66 (6.60, 29.70) | 28.02 (16.07, 30.49) | 0.513 (0.231–1.142) | 0.102 |
Insomnia (SL) | 22 (48.9) | 16 (43.2) | 0.260 | 0.610 | 21.19 (7.66, 27.83) | 26.87 (14.78, 30.06) | 0.656 (0.338–1.274) | 0.213 |
Appetite loss (AP) | 15 (33.3) | 11 (29.7) | 0.122 | 0.727 | 23.95 (9.72, 30.29) | 28.85 (16.07, 30.49) | 0.726 (0.325–1.621) | 0.434 |
Constipation (CO) | 13 (28.9) | 8 (21.6) | 0.563 | 0.453 | 23.85 (9.99, 29.70) | 28.02 (14.78, 30.49) | 0.609 (0.241–1.539) | 0.294 |
Diarrhoea (DI) | 15 (33.3) | 7 (18.9) | 2.149 | 0.143 | 23.95 (12.94, 31.08) | 28.02 (16.07, 30.49) | 0.463 (0.178–1.203) | 0.114 |
Financial difficulties (FI) | 11 (24.4) | 8 (21.6) | 0.091 | 0.763 | 23.95 (8.44, 31.08) | 28.02 (16.36, 30.49) | 0.709 (0.274–1.833) | 0.478 |
QLQ-LC13 | ||||||||
Dyspnoea (LC-DY) | 26 (57.8) | 17 (45.9) | 1.140 | 0.286 | 12.94 (5.19, 25.95) | 25.07 (12.78, 29.40) | 0.593 (0.317–1.112) | 0.103 |
Coughing (LC-CO) | 18 (40.0) | 11 (29.7) | 0.937 | 0.333 | 18.79 (6.54, 29.01) | 28.02 (14.55, 30.49) | 0.543 (0.250–1.179) | 0.123 |
Haemoptysis (LC-HA) | 10 (22.2) | 7 (18.9) | 0.135 | 0.714 | 23.95 (12.94, 31.08) | 28.02 (16.07, 30.49) | 0.656 (0.238–1.807) | 0.414 |
Sore mouth (LC-SM) | 11 (24.4) | 6 (16.2) | 0.837 | 0.360 | 23.95 (12.94, 31.11) | 28.85 (16.36, 30.49) | 0.506 (0.175–1.466) | 0.210 |
Dysphagia (LC-DS) | 10 (22.2) | 8 (21.6) | 0.004 | 0.948 | 23.95 (12.94, 31.08) | 28.02 (16.36, 30.49) | 0.772 (0.293–2.033) | 0.600 |
Peripheral neuropathy (LC-PN) | 11 (24.4) | 10 (27.0) | 0.071 | 0.790 | 23.95 (12.94, 31.08) | 26.25 (14.78, 30.06) | 0.951 (0.394–2.296) | 0.911 |
Alopecia (LC-HR) | 16 (35.6) | 9 (24.3) | 1.209 | 0.272 | 23.66 (10.28, 29.01) | 26.87 (16.07, 30.06) | 0.546 (0.232–1.285) | 0.166 |
Pain in chest (LC-PC) | 20 (44.4) | 11 (29.7) | 1.870 | 0.172 | 15.74 (7.66, 27.14) | 25.95 (14.55, 29.73) | 0.479 (0.224–1.026) | 0.058 |
Pain in aim or should (LC-PA) | 17 (37.8) | 11 (29.7) | 0.585 | 0.444 | 23.85 (8.67, 29.70) | 25.95 (14.78, 29.73) | 0.828 (0.379–1.812) | 0.637 |
Pain in other parts (LC-PO) | 19 (42.2) | 15 (40.5) | 0.024 | 0.878 | 22.93 (8.80, 28.48) | 26.25 (13.37, 29.73) | 0.781 (0.390–1.565) | 0.486 |
Time to deterioration event of Cpn IgGn(%) | χ2 | P | Time to deterioration of Cpn IgGM (P25, P75) | HR (95% CI) | P | |||
---|---|---|---|---|---|---|---|---|
Cpn IgG − | Cpn IgG + | Cpn IgG − | Cpn IgG + | |||||
QLQ-C30 | ||||||||
Global health status (QL) | 13 (65.0) | 39 (62.9) | 0.029 | 0.866 | 21.44 (12.97, 30.05) | 17.41 (6.50, 29.63) | 1.242 (0.648–2.380) | 0.514 |
Functional scales | ||||||||
Physical functioning (PF) | 14 (70.0) | 35 (56.5) | 1.154 | 0.283 | 18.09 (6.27, 25.88) | 15.15 (5.19, 27.97) | 1.126 (0.579–2.190) | 0.726 |
Role functioning (RF) | 10 (50.0) | 23 (37.1) | 1.047 | 0.306 | 21.23 (11.36, 30.05) | 23.95 (5.20, 29.72) | 0.989 (0.454–2.153) | 0.977 |
Emotional functioning (EF) | 11 (55.0) | 15 (24.2) | 6.628 | 0.010 | 18.71 (11.36, 26.06) | 25.95 (13.45, 30.49) | 0.422 (0.189–0.941) | 0.035 |
Cognitive functioning (CF) | 10 (50.0) | 20 (32.3) | 2.052 | 0.152 | 23.76 (14.18, 30.05) | 25.63 (13.33, 29.98) | 0.701 (0.319–1.544) | 0.378 |
Social functioning (SF) | 7 (35.0) | 11 (17.7) | 1.718 | 0.190 | 24.02 (15.45, 31.79) | 26.56 (14.61, 30.49) | 0.632 (0.232–1.718) | 0.368 |
Symptom scales/items | ||||||||
Fatigue (FA) | 8 (40.0) | 19 (30.6) | 0.599 | 0.439 | 23.76 (12.94, 30.05) | 24.00 (8.61, 29.72) | 0.965 (0.405–2.302) | 0.937 |
Nausea and vomiting (NV) | 4 (20.0) | 17 (27.4) | 0.437 | 0.509 | 24.61 (18.03, 34.42) | 26.10 (14.61, 30.44) | 1.999 (0.585–6.829) | 0.269 |
Pain (PA) | 12 (60.0) | 27 (43.5) | 1.641 | 0.200 | 18.71 (8.93, 29.18) | 17.41 (5.44, 28.85) | 0.900 (0.443–1.831) | 0.771 |
Dyspnoea (DY) | 9 (45.0) | 20 (32.3) | 1.074 | 0.300 | 24.12 (14.18, 31.79) | 25.19 (10.06, 29.98) | 0.914 (0.400–2.088) | 0.831 |
Insomnia (SL) | 12 (60.0) | 26 (741.9) | 1.985 | 0.159 | 20.86 (8.94, 30.75) | 24.56 (10.41, 29.63) | 0.769 (0.378–1.565) | 0.469 |
Appetite loss (AP) | 7 (35.0) | 19 (30.6) | 0.132 | 0.716 | 24.02 (14.18, 31.79) | 25.95 (13.67, 30.44) | 1.077 (0.429–2.704) | 0.875 |
Constipation (CO) | 7 (35.0) | 14 (22.6) | 1.224 | 0.269 | 23.76 (14.18, 30.05) | 25.63 (13.33, 30.23) | 0.771 (0.296–2.010) | 0.595 |
Diarrhoea (DI) | 5 (25.0) | 17 (27.4) | 0.045 | 0.832 | 24.12 (15.45, 31.79) | 26.10 (13.67, 30.44) | 1.387 (0.466–4.128) | 0.557 |
Financial difficulties (FI) | 7 (35.0) | 12 (19.4) | 1.293 | 0.256 | 21.23 (11.36, 30.05) | 26.56 (14.61, 30.49) | 0.605 (0.227–1.613) | 0.315 |
QLQ-LC13 | ||||||||
Dyspnoea (LC-DY) | 13 (65.0) | 30 (48.4) | 1.673 | 0.196 | 15.79 (6,25, 29.18) | 20.75 (7.85, 28.85) | 0.865 (0.438–1.707) | 0.675 |
Coughing (LC-CO) | 8 (40.0) | 21 (33.9) | 0.249 | 0.618 | 24.02 (8.93, 32.30) | 24.00 (8.50, 29.72) | 0.965 (0.410–2.271) | 0.935 |
Haemoptysis (LC-HA) | 5 (25.0) | 12 (19.4) | 0.050 | 0.823 | 24.12 (15.45, 31.79) | 26.10 (13.67, 30.44) | 0.973 (0.313–3.019) | 0.962 |
Sore mouth (LC-SM) | 5 (25.0) | 12 (19.4) | 0.050 | 0.823 | 24.61 (18.03, 34.42) | 26.10 (14.61, 30.49) | 1.086 (0.349–3.383) | 0.887 |
Dysphagia (LC-DS) | 6 (30.0) | 12 (19.4) | 0.475 | 0.491 | 23.76 (15.45, 30.05) | 26.56 (15.10, 30.49) | 0.737 (0.259–2.096) | 0.567 |
Peripheral neuropathy (LC-PN) | 7 (35.0) | 14 (22.6) | 1.224 | 0.269 | 23.76 (15.45, 30.05) | 25.95 (13.33, 30.44) | 0.746 (0.286–1.945) | 0.549 |
Alopecia (LC-HR) | 9 (45.0) | 16 (25.8) | 2.629 | 0.105 | 23.30 (13.11, 29.18) | 25.63 (13.33, 29.98) | 0.617 (0.264–1.444) | 0.266 |
Pain in chest (LC-PC) | 9 (45.0) | 22 (35.5) | 0.582 | 0.445 | 20.86 (12.94, 29.18) | 22.11 (8.27, 28.99) | 0.985 (0.439–2.214) | 0.972 |
Pain in aim or should (LC-PA) | 9 (45.0) | 19 (30.6) | 1.386 | 0.239 | 23.30 (15.45, 29.18) | 25.19 (10.02, 29.98) | 0.635 (0.285–1.417) | 0.267 |
Pain in other parts (LC-PO) | 12 (60.0) | 22 (35.5) | 3.745 | 0.053 | 23.30 (14.18, 29.18) | 23.95 (8.78, 29.63) | 0.723 (0.348–1.503) | 0.385 |
Time to deterioration event of Cpn IgAIgGn(%) | χ2 | P | Time to deterioration of Cpn IgAIgGM (P25, P75) | HR (95% CI) | P | |||||
---|---|---|---|---|---|---|---|---|---|---|
Cpn IgA-IgG- | Cpn IgA + IgG-/IgA-IgG + | Cpn IgA + IgG + | Cpn IgA-IgG- | Cpn IgA + IgG-/IgA-IgG + | Cpn IgA + IgG + | |||||
QLQ-C30 | ||||||||||
Global health status (QL) | 10 (58.8) | 23 (74.2) | 19 (55.9) | 2.538 | 0.281 | 19.94 (12.94, 29.70) | 11.96 (4.54, 26.55) | 27.45 (13.33, 29.98) | 0.916 (0.645–1.300) | 0.623 |
Functional scales | ||||||||||
Physical functioning (PF) | 11 (64.7) | 23 (74.2) | 15 (44.1) | 6.318 | 0.042 | 15.74 (5.45, 24.84) | 9.99 (4.62, 23.95) | 24.81 (13.67, 29.31) | 0.786 (0.550–1.123) | 0.186 |
Role functioning (RF) | 7 (41.2) | 17 (54.8) | 9 (26.5) | 5.434 | 0.066 | 18.79 (6.60, 29.70) | 18.63 (4.62, 28.16) | 27.45 (14.61, 29.98) | 0.802 (0.515–1.249) | 0.328 |
Emotional functioning (EF) | 9 (52.9) | 9 (29.0) | 8 (23.5) | 4.692 | 0.096 | 15.74 (6.60, 24.84) | 24.38 (11.12, 31.85) | 27.45 (14.61, 30.38) | 0.591 (0.354–0.988) | 0.045 |
Cognitive functioning (CF) | 8 (47.1) | 11 (35.5) | 11 (32.4) | 1.083 | 0.582 | 23.66 (12.94, 29.70) | 24.05 (12.57, 30.70) | 26.56 (14.61, 29.72) | 0.800 (0.500–1.279) | 0.351 |
Social functioning (SF) | 5 (29.4) | 8 (25.8) | 5 (14.7) | 0.399 | 23.66 (14.59, 31.08) | 24.38 (11.12, 31.85) | 28.44 (16.14, 30.38) | 0.717 (0.387–1.328) | 0.290 | |
Symptom scales/items | ||||||||||
Fatigue (FA) | 7 (41.2) | 11 (35.5) | 9 (26.5) | 1.257 | 0.533 | 18.79 (12.94, 29.01) | 23.95 (6.12, 30.70) | 26.56 (13.67, 29.72) | 0.790 (0.481–1.296) | 0.350 |
Nausea and vomiting (NV) | 3 (17.6) | 10 (32.3) | 8 (23.5) | 0.549 | 23.85 (15.74, 31.08) | 24.38 (11.12, 31.85) | 28.44 (16.14, 30.38) | 1.056 (0.593–1.879) | 0.853 | |
Pain (PA) | 10 (58.8) | 16 (51.6) | 13 (38.2) | 2.254 | 0.324 | 14.59 (6.54, 29.01) | 10.28 (5.19, 25.63) | 24.96 (12.91, 29.63) | 0.791 (0.527–1.187) | 0.257 |
Dyspnoea (DY) | 8 (47.1) | 12 (38.7) | 9 (26.5) | 2.345 | 0.310 | 23.66 (12.94, 29.70) | 23.95 (7.00, 30.70) | 27.45 (15.10, 29.98) | 0.745 (0.462–1.201) | 0.226 |
Insomnia (SL) | 11 (64.7) | 12 (38.7) | 15 (44.1) | 3.099 | 0.212 | 15.47 (6.60, 24.84) | 23.95 (9.22, 29.39) | 26.56 (14.78, 29.72) | 0.761 (0.498–1.162) | 0.206 |
Appetite loss (AP) | 6 (35.3) | 10 (32.3) | 10 (29.4) | 0.188 | 0.910 | 22.93 (12.94, 29.70) | 24.38 (9.66, 31.85) | 28.44 (15.10, 30.38) | 0.894 (0.535–1.494) | 0.669 |
Constipation (CO) | 6 (35.3) | 8 (25.8) | 7 (20.6) | 0.519 | 22.93 (12.94, 29.01) | 24.38 (9.66, 31.85) | 27.45 (14.61, 29.98) | 0.743 (0.419–1.321) | 0.312 | |
Diarrhoea (DI) | 4 (23.5) | 12 (38.7) | 6 (17.6) | 0.157 | 23.66 (14.59, 29.70) | 25.30 (11.73, 35.09) | 27.45 (15.10, 29.98) | 0.801 (0.449–1.430) | 0.453 | |
Financial difficulties (FI) | 5 (29.4) | 8 (25.8) | 6 (17.6) | 0.624 | 18.79 (6.60, 29.70) | 24.38 (10.14, 31.85) | 28.44 (16.14, 30.38) | 0.728 (0.400–1.324) | 0.298 | |
QLQ-LC13 | ||||||||||
Dyspnoea (LC-DY) | 11 (64.7) | 17 (54.8) | 15 (44.1) | 2.041 | 0.360 | 12.94 (5.39, 29.01) | 14.36 (5.19, 25.17) | 25.51 (9.95, 29.31) | 0.769 (0.521–1.135) | 0.185 |
Coughing (LC-CO) | 7 (41.2) | 12 (38.7) | 10 (29.4) | 0.930 | 0.628 | 18.79 (6.54, 29.70) | 23.95 (8.05, 29.39) | 27.45 (13.67, 30.30) | 0.773 (0.482–1.239) | 0.285 |
Haemoptysis (LC-HA) | 4 (23.5) | 7 (22.6) | 6 (17.6) | 0.826 | 23.66 (14.59, 29.70) | 25.30 (11.73, 35.09) | 27.45 (15.10, 29.98) | 0.832 (0.441–1.569) | 0.570 | |
Sore mouth (LC-SM) | 4 (23.5) | 8 (25.8) | 5 (14.7) | 0.466 | 23.85 (15.74, 31.08) | 24.38 (11.12, 35.09) | 28.44 (16.14, 30.38) | 0.785 (0.418–1.476) | 0.453 | |
Dysphagia (LC-DS) | 4 (23.5) | 8 (25.8) | 6 (17.6) | 0.738 | 23.66 (14.59, 29.70) | 24.38 (15.21, 31.85) | 28.44 (16.14, 30.38) | 0.810 (0.438–1.500) | 0.503 | |
Peripheral neuropathy (LC-PN) | 5 (29.4) | 8 (25.8) | 8 (23.5) | 0.946 | 23.66 (14.59, 29.70) | 24.38 (15.21, 31.85) | 26.56 (13.72, 29.98) | 0.886 (0.501–1.569) | 0.679 | |
Alopecia (LC-HR) | 7 (41.2) | 11 (35.5) | 7 (20.6) | 2.854 | 0.240 | 22.93 (12.94, 29.01) | 23.95 (10.53, 29.39) | 27.45 (15.10, 29.98) | 0.661 (0.393–1.111) | 0.118 |
Pain in chest (LC-PC) | 7 (41.2) | 15 (48.4) | 9 (26.5) | 3.416 | 0.181 | 18.79 (12.94, 29.01) | 18.46 (6.89, 26.55) | 26.41 (13.67, 29.72) | 0.756 (0.486–1.176) | 0.214 |
Pain in aim or should (LC-PA) | 7 (41.2) | 12 (38.7) | 9 (26.5) | 1.552 | 0.460 | 23.66 (14.59, 29.70) | 23.95 (9.00, 28.16) | 27.45 (13.72, 29.98) | 0.793 (0.487–1.290) | 0.350 |
Pain in other parts (LC-PO) | 9 (52.9) | 13 (41.9) | 12 (35.3) | 1.459 | 0.482 | 22.93 (12.94, 29.01) | 23.03 (8.56, 28.16) | 26.56 (13.33, 29.72) | 0.811 (0.525–1.251) | 0.343 |
Variable | Items | HR (95%CI) | P |
---|---|---|---|
QLQ-C30 | |||
Cpn IgA | Physical functioning (PF) | 0.539 (0.291–0.996) | 0.048 |
Cpn IgG | Emotional functioning (EF) | 0.310 (0.115–0.836) | 0.021 |